<s id="wsj_1443.1"> 30
1 	 0 	 N/N 	 1 	 Corp. Immunex
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Corp. said
4 	 3 	 NP[nb]/N 	 1 	 scientists its
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 scientists isolated
5 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 isolated said
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 molecule isolated
7 	 6 	 NP[nb]/N 	 1 	 molecule a
7 	 8 	 (NP\NP)/(S[dcl]\NP) 	 1 	 molecule which
7 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 molecule may <XB>
7 	 10 	 (S[b]\NP)/NP 	 1 	 molecule hold <XB>
9 	 8 	 (NP\NP)/(S[dcl]\NP) 	 2 	 may which
10 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 hold may
11 	 10 	 (S[b]\NP)/NP 	 2 	 potential hold
11 	 12 	 (NP\NP)/NP 	 1 	 potential as
14 	 12 	 (NP\NP)/NP 	 2 	 treatment as
14 	 13 	 NP[nb]/N 	 1 	 treatment a
14 	 15 	 (NP\NP)/NP 	 1 	 treatment for
16 	 15 	 (NP\NP)/NP 	 2 	 disruptions for
16 	 17 	 (NP\NP)/NP 	 1 	 disruptions of
16 	 21 	 S[ng]\NP 	 1 	 disruptions ranging <XB>
19 	 17 	 (NP\NP)/NP 	 2 	 immune-system of
19 	 18 	 NP[nb]/N 	 1 	 immune-system the
21 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 ranging from
21 	 26 	 ((S\NP)\(S\NP))/NP 	 2 	 ranging to
24 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 rejection from
24 	 23 	 N/N 	 1 	 rejection organ-transplant
27 	 26 	 ((S\NP)\(S\NP))/NP 	 3 	 allergies to
29 	 26 	 ((S\NP)\(S\NP))/NP 	 3 	 asthma to
<\s>
<s id="wsj_1443.2"> 13
1 	 0 	 NP[nb]/N 	 1 	 molecule The
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 molecule is
5 	 2 	 (S[dcl]\NP)/NP 	 2 	 version is
5 	 3 	 NP[nb]/N 	 1 	 version the
5 	 4 	 N/N 	 1 	 version mouse
5 	 6 	 (NP\NP)/NP 	 1 	 version of
8 	 6 	 (NP\NP)/NP 	 2 	 protein of
8 	 7 	 NP[nb]/N 	 1 	 protein a
8 	 9 	 (S[pss]\NP)/NP 	 1 	 protein called <XB>
12 	 9 	 (S[pss]\NP)/NP 	 2 	 receptor called
12 	 10 	 NP[nb]/N 	 1 	 receptor the
12 	 11 	 N/N 	 1 	 receptor interleukin-4
<\s>
<s id="wsj_1443.3"> 21
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 IL-4 is
3 	 1 	 (S[dcl]\NP)/NP 	 2 	 hormone is
3 	 2 	 NP[nb]/N 	 1 	 hormone a
3 	 4 	 (NP\NP)/(S[dcl]\NP) 	 1 	 hormone which
3 	 5 	 (S[dcl]\NP)/NP 	 1 	 hormone directs <XB>
5 	 4 	 (NP\NP)/(S[dcl]\NP) 	 2 	 directs which
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 growth directs
7 	 6 	 NP[nb]/N 	 1 	 growth the
7 	 10 	 (NP\NP)/NP 	 1 	 growth of
9 	 5 	 (S[dcl]\NP)/NP 	 2 	 function directs
9 	 6 	 NP[nb]/N 	 1 	 function the
9 	 10 	 (NP\NP)/NP 	 1 	 function of
13 	 10 	 (NP\NP)/NP 	 2 	 cells of
13 	 11 	 N/N 	 1 	 cells white
13 	 12 	 N/N 	 1 	 cells blood
13 	 14 	 (S[pss]\NP)/PP 	 1 	 cells involved <XB>
15 	 14 	 (S[pss]\NP)/PP 	 2 	 in involved
17 	 16 	 NP[nb]/N 	 1 	 body the
17 	 18 	 (NP[nb]/N)\NP 	 2 	 body 's
20 	 15 	 PP/NP 	 1 	 response in
20 	 18 	 (NP[nb]/N)\NP 	 1 	 response 's
20 	 19 	 N/N 	 1 	 response immune
<\s>
<s id="wsj_1443.4"> 20
2 	 0 	 NP[nb]/N 	 1 	 receptor The
2 	 1 	 N/N 	 1 	 receptor IL-4
2 	 3 	 (NP\NP)/NP 	 1 	 receptor on
2 	 9 	 (S[dcl]\NP)/NP 	 1 	 receptor receives
5 	 3 	 (NP\NP)/NP 	 2 	 surface on
5 	 4 	 NP[nb]/N 	 1 	 surface the
5 	 6 	 (NP\NP)/NP 	 1 	 surface of
8 	 6 	 (NP\NP)/NP 	 2 	 cells of
8 	 7 	 NP/NP 	 1 	 cells such
11 	 10 	 NP[nb]/N 	 1 	 hormone the
11 	 12 	 (NP[nb]/N)\NP 	 2 	 hormone 's
13 	 9 	 (S[dcl]\NP)/NP 	 2 	 message receives
13 	 12 	 (NP[nb]/N)\NP 	 1 	 message 's
13 	 15 	 (S[b]\NP)/NP 	 1 	 message rally <XB>
15 	 14 	 (S[to]\NP)/(S[b]\NP) 	 2 	 rally to
17 	 16 	 NP[nb]/N 	 1 	 body the
17 	 18 	 (NP[nb]/N)\NP 	 2 	 body 's
19 	 15 	 (S[b]\NP)/NP 	 2 	 defense rally
19 	 18 	 (NP[nb]/N)\NP 	 1 	 defense 's
<\s>
<s id="wsj_1443.5"> 35
3 	 1 	 (S/S)/NP 	 2 	 conditions in
3 	 2 	 N/N 	 1 	 conditions certain
3 	 5 	 (NP\NP)/NP 	 1 	 conditions as
5 	 4 	 (NP\NP)/(NP\NP) 	 2 	 as such
7 	 5 	 (NP\NP)/NP 	 2 	 diseases as
7 	 6 	 N/N 	 1 	 diseases autoimmune
9 	 5 	 (NP\NP)/NP 	 2 	 allergies as
12 	 5 	 (NP\NP)/NP 	 2 	 rejection as
12 	 11 	 N/N 	 1 	 rejection transplant
14 	 15 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 doctors would
14 	 16 	 (S[b]\NP)/(S[to]\NP) 	 1 	 doctors like <XB>
14 	 18 	 (S[b]\NP)/NP 	 1 	 doctors damp <XB>
15 	 0 	 S/S 	 1 	 would But
15 	 1 	 (S/S)/NP 	 1 	 would in
16 	 15 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 like would
17 	 16 	 (S[b]\NP)/(S[to]\NP) 	 2 	 to like
18 	 17 	 (S[to]\NP)/(S[b]\NP) 	 2 	 damp to
18 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 damp so
21 	 18 	 (S[b]\NP)/NP 	 2 	 response damp
21 	 19 	 NP[nb]/N 	 1 	 response the
21 	 20 	 N/N 	 1 	 response immune
24 	 23 	 NP/NP 	 1 	 cells such
24 	 25 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 cells do
24 	 27 	 (S[b]\NP)/NP 	 1 	 cells touch <XB>
25 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 do so
25 	 26 	 (S\NP)\(S\NP) 	 2 	 do n't
27 	 25 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 touch do
27 	 28 	 (S\NP)\(S\NP) 	 2 	 touch off
31 	 27 	 (S[b]\NP)/NP 	 2 	 reactions touch
31 	 29 	 N/N 	 1 	 reactions harmful
31 	 30 	 N/N 	 1 	 reactions inflammatory
34 	 27 	 (S[b]\NP)/NP 	 2 	 destruction touch
34 	 33 	 N/N 	 1 	 destruction cell
<\s>
<s id="wsj_1443.6"> 24
2 	 0 	 NP[nb]/N 	 1 	 form A
2 	 1 	 N/N 	 1 	 form soluble
2 	 3 	 (NP\NP)/NP 	 1 	 form of
2 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 form might
2 	 7 	 (S[b]\NP)/NP 	 1 	 form turn <XB>
5 	 3 	 (NP\NP)/NP 	 2 	 receptor of
5 	 4 	 NP[nb]/N 	 1 	 receptor the
6 	 23 	 (S[dcl]\S[dcl])\NP 	 1 	 might said
7 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 turn might
7 	 8 	 (S\NP)\(S\NP) 	 2 	 turn off
7 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 turn without
11 	 7 	 (S[b]\NP)/NP 	 2 	 part turn
11 	 9 	 NP[nb]/N 	 1 	 part a
11 	 10 	 N/N 	 1 	 part specific
11 	 12 	 (NP\NP)/NP 	 1 	 part of
15 	 12 	 (NP\NP)/NP 	 2 	 response of
15 	 13 	 NP[nb]/N 	 1 	 response the
15 	 14 	 N/N 	 1 	 response immune
19 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 suppression without
19 	 17 	 N/N 	 1 	 suppression general
19 	 18 	 N/N 	 1 	 suppression immune
22 	 21 	 NP[nb]/N 	 1 	 company the
22 	 23 	 (S[dcl]\S[dcl])\NP 	 2 	 company said
<\s>
<s id="wsj_1443.7"> 32
2 	 0 	 NP[nb]/N 	 1 	 receptor The
2 	 1 	 N/N 	 1 	 receptor IL-4
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 receptor is
4 	 3 	 (S[dcl]\NP)/NP 	 2 	 one is
4 	 5 	 (NP\NP)/NP 	 1 	 one of
8 	 5 	 (NP\NP)/NP 	 2 	 receptors of
8 	 6 	 N/N 	 1 	 receptors five
8 	 7 	 N/N 	 1 	 receptors such
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
11 	 10 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 developed be
11 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 developed by
11 	 23 	 ((S\NP)\(S\NP))/NP 	 2 	 developed through
13 	 10 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 tested be
13 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 tested by
13 	 23 	 ((S\NP)\(S\NP))/NP 	 2 	 tested through
16 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 Corp. by
16 	 15 	 N/N 	 1 	 Corp. Receptech
19 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 spinoff by
19 	 18 	 NP[nb]/N 	 1 	 spinoff a
19 	 20 	 (NP\NP)/NP 	 1 	 spinoff of
21 	 20 	 (NP\NP)/NP 	 2 	 Immunex of
28 	 26 	 (N/N)/N[num] 	 2 	 million $
28 	 27 	 N/N 	 1 	 million 30
31 	 23 	 ((S\NP)\(S\NP))/NP 	 3 	 offering through
31 	 24 	 NP[nb]/N 	 1 	 offering a
31 	 25 	 N/N 	 1 	 offering proposed
31 	 26 	 (N/N)/N[num] 	 1 	 offering $
31 	 29 	 N/N 	 1 	 offering initial
31 	 30 	 N/N 	 1 	 offering public
<\s>
<s id="wsj_1443.8"> 19
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Immunex will
0 	 2 	 (S[b]\NP)/PP 	 1 	 Immunex contract <XB>
0 	 7 	 (S[b]\NP)/NP 	 1 	 Immunex provide <XB>
2 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 contract will
3 	 2 	 (S[b]\NP)/PP 	 2 	 with contract
5 	 3 	 PP/NP 	 1 	 spinoff with
5 	 4 	 NP[nb]/N 	 1 	 spinoff the
7 	 6 	 (S[to]\NP)/(S[b]\NP) 	 2 	 provide to
9 	 7 	 (S[b]\NP)/NP 	 2 	 research provide
9 	 8 	 NP[nb]/N 	 1 	 research the
11 	 7 	 (S[b]\NP)/NP 	 2 	 development provide
14 	 7 	 (S[b]\NP)/NP 	 2 	 testing provide
14 	 13 	 N/N 	 1 	 testing initial
14 	 15 	 (NP\NP)/NP 	 1 	 testing of
18 	 15 	 (NP\NP)/NP 	 2 	 agents of
18 	 16 	 NP[nb]/N 	 1 	 agents the
18 	 17 	 N/N 	 1 	 agents new
<\s>
<s id="wsj_1443.9"> 13
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Immunex will
0 	 2 	 (S[b]\NP)/NP 	 1 	 Immunex have <XB>
2 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have will
4 	 2 	 (S[b]\NP)/NP 	 2 	 option have
4 	 3 	 NP[nb]/N 	 1 	 option the
4 	 6 	 (S[b]\NP)/NP 	 1 	 option buy <XB>
6 	 5 	 (S[to]\NP)/(S[b]\NP) 	 2 	 buy to
6 	 7 	 (S\NP)\(S\NP) 	 2 	 buy back
6 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 buy after
9 	 6 	 (S[b]\NP)/NP 	 2 	 shares buy
9 	 8 	 N/N 	 1 	 shares Receptech
12 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 years after
12 	 11 	 N/N 	 1 	 years five
<\s>
